Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $114.7 million.

  • Iradimed's Liabilities and Shareholders Equity rose 2172.49% to $114.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $421.2 million, marking a year-over-year increase of 1560.46%. This contributed to the annual value of $98.3 million for FY2024, which is 669.48% up from last year.
  • Iradimed's Liabilities and Shareholders Equity amounted to $114.7 million in Q3 2025, which was up 2172.49% from $106.4 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Liabilities and Shareholders Equity registered a high of $114.7 million during Q3 2025, and its lowest value of $72.2 million during Q1 2021.
  • Over the past 5 years, Iradimed's median Liabilities and Shareholders Equity value was $85.5 million (recorded in 2022), while the average stood at $87.0 million.
  • Per our database at Business Quant, Iradimed's Liabilities and Shareholders Equity increased by 19.08% in 2022 and then surged by 2172.49% in 2025.
  • Quarter analysis of 5 years shows Iradimed's Liabilities and Shareholders Equity stood at $82.9 million in 2021, then grew by 3.18% to $85.5 million in 2022, then increased by 7.77% to $92.2 million in 2023, then rose by 6.69% to $98.3 million in 2024, then grew by 16.68% to $114.7 million in 2025.
  • Its last three reported values are $114.7 million in Q3 2025, $106.4 million for Q2 2025, and $101.7 million during Q1 2025.